CellSeal References
Protocol
2025 | CellSeal® References | Protocol
NEOadjuvant dendritic cell therapy added to first line standard of care in advanced epithelial ovarian cancer (NEODOC): protocol of a first-in-human, exploratory, single-centre phase I/II trial in the Netherlands.
Authors: Duiveman-de Boer T, de Goede A, Bos K, Westdorp H, van Oorschot T, van Ham M, Pots J, de Vries IJM, Scharenborg N, Ottevanger PB., de Boer A, Koeneman B, Hins-de Bree S, Schreibelt G, de Haas N
Published: BMJ Open; 09 November 2025; Volume 15, Issue 11, e102184